How should oral (PO) phenytoin be converted to an equivalent intravenous (IV) dose?

Converting Oral to IV Phenytoin

When converting from oral to IV phenytoin, use 18 mg/kg IV (versus 20 mg/kg oral) due to the approximately 8% higher bioavailability of the free acid form used in oral formulations compared to the sodium salt used in IV preparations. 1

Dosing Conversion Algorithm

Key Principle

The conversion is not 1:1 because of formulation differences:

• Oral phenytoin (suspension/tablets): Contains free acid form
• IV phenytoin: Contains sodium salt form
• The free acid form has ~8% more drug content than the sodium salt 1

Standard Loading Doses

• Oral loading: 20 mg/kg divided into maximum 400 mg doses every 2 hours 2, 1
• IV phenytoin loading: 18 mg/kg at maximum rate of 50 mg/min 2
• IV fosphenytoin loading: 18 PE/kg at maximum rate of 150 PE/min 2

Maintenance Dose Conversion

When switching from established oral to IV therapy:

• Monitor serum levels closely as bioavailability differences require adjustment 1
• Oral bioavailability ranges 57-86% in studies 3, 4, though FDA labeling accounts for this in standard dosing
• Practical approach: Start with the same total daily dose in mg, but expect to need adjustments based on serum levels

Critical Timing Differences

Oral phenytoin takes >5 hours to reach therapeutic levels (mean 5.62 hours), while IV phenytoin achieves therapeutic levels in ~15 minutes (mean 0.24 hours) 5. This makes route selection clinically important:

• Choose IV when: Rapid therapeutic levels needed (active seizures, status epilepticus)
• Choose oral when: No urgency for immediate levels, fewer adverse events acceptable trade-off for slower onset 5

Important Safety Considerations

IV Administration Hazards

IV phenytoin carries significantly more serious risks than oral 2:

• Hypotension
• Bradyarrhythmias
• Cardiac arrest
• Extravasation injuries
• Requires filter and infusion pump 2

Oral loading had significantly fewer adverse events (17 events) compared to IV phenytoin (27 events) in head-to-head comparison 5

Monitoring Requirements

• Serum level monitoring is mandatory when converting between formulations 1
• Steady-state requires 7-10 days (5-7 half-lives) 1
• Therapeutic range: 10-20 mcg/mL 1
• Check levels before making any dosage adjustments within the 7-10 day window 1

Common Pitfalls to Avoid

1. Don't assume 1:1 conversion: The 8% difference matters, especially at higher doses where phenytoin exhibits saturable kinetics 1

2. Don't make premature dose adjustments: Small incremental changes can produce disproportionate increases in serum levels due to saturable metabolism 1

3. Don't use extended-release capsules for divided dosing: Only Dilantin extended capsules are appropriate for once-daily dosing 1

4. Don't forget protein binding: Free phenytoin levels may differ significantly in patients with altered protein binding despite similar total levels 1